Completed PHASE3 INTERVENTIONAL 2-arm NCT01626677

Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect

Long Term Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee

Sponsor: Dong-A Pharmaceutical Co., Ltd.

Conditions Defect of Articular Cartilage Degenerative Osteoarthritis

Updated 7 times since 2017 Last updated: Apr 19, 2017 Started: Jun 30, 2012 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01626677, this PHASE3 trial focuses on Defect of Articular Cartilage and Degenerative Osteoarthritis and remains completed. Sponsored by Dong-A Pharmaceutical Co., Ltd., it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — May 2017 [monthly]

Completed PHASE3

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A Pharmaceutical Co., Ltd.
Medipost Co Ltd.

Data source: Medipost Co Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Incheon, South Korea
• Seoul, South Korea